Cargando…

A path forward for Swedish drug policy?

AIMS AND PREMISE: The primary aims of this article are to: describe some major aspects of the theoretical basis of the Swedish drug policy model, present alternative theoretical understandings which may pave the way for changes in drug policy, depict some problems with the Swedish model, introduce t...

Descripción completa

Detalles Bibliográficos
Autor principal: Goldberg, Ted
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899069/
https://www.ncbi.nlm.nih.gov/pubmed/35310003
http://dx.doi.org/10.1177/1455072520978352
_version_ 1784663823162015744
author Goldberg, Ted
author_facet Goldberg, Ted
author_sort Goldberg, Ted
collection PubMed
description AIMS AND PREMISE: The primary aims of this article are to: describe some major aspects of the theoretical basis of the Swedish drug policy model, present alternative theoretical understandings which may pave the way for changes in drug policy, depict some problems with the Swedish model, introduce the primary principles for “the experimenting society”, and give concrete examples of when these have/have not been applied in Sweden. SOME FINDINGS: Sweden’s predominantly biochemical approach should be replaced by a biopsychosocial model. The idea that all non-medical consumption of drugs is abuse is counterproductive. Differences between recreational and problematic consumers are discussed. The question of people’s motives for taking drugs has not been incorporated into Swedish drug policy. The stepping-stone hypothesis is examined. It was found that recreational and problematic consumption do not co-vary, indicating that these are two essentially different phenomena. CONCLUSION: After four decades with the current Swedish drug policy model we are further from our pronounced goal of striving towards becoming a drug-free society than when we started. Access to, and demand for, drugs has continually increased, and our drug policies have caused serious collateral damage. Consequently, there is good reason to re-think the course we have chosen. The Swedish version of the war on drugs has failed to achieve its goals and it is time to make peace. It is time to accept that we will never be drug-free and therefore must learn to live with narcotics. As nobody knows what is the best way to achieve this, we should approach the task with humility. We need to put prestige aside and become “the experimenting society”; that is, one that would vigorously try out possible solutions and make stringent, multidimensional evaluations of outcomes. When the evaluation of a reform shows it to have been ineffective or harmful, we should try other measures.
format Online
Article
Text
id pubmed-8899069
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88990692022-03-17 A path forward for Swedish drug policy? Goldberg, Ted Nordisk Alkohol Nark For Debate AIMS AND PREMISE: The primary aims of this article are to: describe some major aspects of the theoretical basis of the Swedish drug policy model, present alternative theoretical understandings which may pave the way for changes in drug policy, depict some problems with the Swedish model, introduce the primary principles for “the experimenting society”, and give concrete examples of when these have/have not been applied in Sweden. SOME FINDINGS: Sweden’s predominantly biochemical approach should be replaced by a biopsychosocial model. The idea that all non-medical consumption of drugs is abuse is counterproductive. Differences between recreational and problematic consumers are discussed. The question of people’s motives for taking drugs has not been incorporated into Swedish drug policy. The stepping-stone hypothesis is examined. It was found that recreational and problematic consumption do not co-vary, indicating that these are two essentially different phenomena. CONCLUSION: After four decades with the current Swedish drug policy model we are further from our pronounced goal of striving towards becoming a drug-free society than when we started. Access to, and demand for, drugs has continually increased, and our drug policies have caused serious collateral damage. Consequently, there is good reason to re-think the course we have chosen. The Swedish version of the war on drugs has failed to achieve its goals and it is time to make peace. It is time to accept that we will never be drug-free and therefore must learn to live with narcotics. As nobody knows what is the best way to achieve this, we should approach the task with humility. We need to put prestige aside and become “the experimenting society”; that is, one that would vigorously try out possible solutions and make stringent, multidimensional evaluations of outcomes. When the evaluation of a reform shows it to have been ineffective or harmful, we should try other measures. SAGE Publications 2021-02-09 2021-04 /pmc/articles/PMC8899069/ /pubmed/35310003 http://dx.doi.org/10.1177/1455072520978352 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle For Debate
Goldberg, Ted
A path forward for Swedish drug policy?
title A path forward for Swedish drug policy?
title_full A path forward for Swedish drug policy?
title_fullStr A path forward for Swedish drug policy?
title_full_unstemmed A path forward for Swedish drug policy?
title_short A path forward for Swedish drug policy?
title_sort path forward for swedish drug policy?
topic For Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899069/
https://www.ncbi.nlm.nih.gov/pubmed/35310003
http://dx.doi.org/10.1177/1455072520978352
work_keys_str_mv AT goldbergted apathforwardforswedishdrugpolicy
AT goldbergted pathforwardforswedishdrugpolicy